ISSN: 2755-0184

Journal of Diabetes Research Reviews & Reports

SCIENTIFIC Research and Community

Review Article

Open Access

Gastrointestinal Manifestations of Diabetes: A Comprehensive Review of Complications, Mechanisms and Emerging Therapeutic Strategies

Ashita Rukmini Vuthaluru[1], Srineil Vuthaluru[2], FNU Suhani[3], Priyadeep Kaur[4] and Manjeet Kumar Goyal[5*]

[1]All India Institute of Medical Sciences, New Delhi, India

[2]Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska

[3]Dayanand Medical College and Hospital, India

[4]Punjab Institute of Medical Sciences, India

[5]IBD Fellow, DM Gastroenterology, MBBS, MD Internal Medicine, DNB Internal Medicine, All India Institute of Medical Sciences, New Delhi, India

***Corresponding author**
Manjeet Kumar Goyal, IBD Fellow, DM Gastroenterology, MBBS, MD Internal Medicine, DNB Internal Medicine, All India Institute of Medical Sciences, New Delhi, India.

Received: April 10, 2024; **Accepted:** April 17, 2024; **Published:** April 24, 2024

Introduction

Diabetes mellitus, characterized by persistent hyperglycemia, is a multifaceted metabolic disorder with escalating global prevalence and significant health implications. Traditional research and clinical focus have centered on its vascular complications. However, the Gastrointestinal (GI) manifestations of diabetes represent a critical yet underexplored domain with substantial impact on patient quality of life and disease management. These manifestations encompass a spectrum of disorders ranging from oropharyngeal dysphagia to lower GI tract symptoms like constipation, diarrhea, and enteropathy. The pathophysiology underlying these conditions is complex, implicating autonomic neuropathy, glycemic variability, gut motility changes, microbiota alterations, and hormonal disruptions.

In light of the rising diabetes incidence, understanding its GI manifestations is imperative for advancing clinical practice and patient care. This review contributes to the academic discourse by delineating the intersection between diabetes and GI health, underscoring the need for heightened awareness and specialized knowledge among healthcare professionals.

Epidemiology

GI symptoms are prevalent among individuals with diabetes, with studies indicating a higher frequency compared to the non-diabetic population. According to the International Diabetes Federation (IDF), approximately 463 million adults (20-79 years) were living with diabetes in 2019, and this number is expected to rise to 700 million by 2045. The global prevalence underscores the potential scale of GI manifestations within this population [1]. The prevalence of GI symptoms in diabetes varies widely across studies, partly due to differences in the populations studied, the definitions of GI symptoms used, and the methods of as sessment. For instance, a study by Bytzer et al. reported that GI symptoms were present in up to 75% of diabetic patients, a significantly higher rate than in the general population. Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, is notably more common in diabetes, with prevalence rates ranging from 5% to 12% in patients with diabetes [2]. Other common GI manifestations in diabetes include GERD, constipation, diarrhea, and Nonalcoholic Fatty Liver Disease (NAFLD) [3].

Prevalence of GI Manifestations in Diabetes

- **Gastroparesis:** Gastroparesis is one of the most studied GI manifestations in diabetes. Studies have reported its prevalence to be between 5% to 12% among patients with diabetes. A study by Horowitz et al. highlighted that gastroparesis symptoms were present in up to 50% of patients with long-standing type 1 and type 2 diabetes, although not all had delayed gastric emptying [4].
- **Gastroesophageal Reflux Disease (GERD):** GERD is more common in individuals with diabetes compared to the general population. The prevalence of GERD symptoms in diabetic patients ranges from 25% to 41%, as reported by various studies. A systematic review by Miftahussurur et al. indicated that diabetic patients have a significantly higher risk of GERD compared to non-diabetics, with odds ratios ranging from 1.5 to 2.0 [5].
- **Constipation and Diarrhea:** Constipation is reported in approximately 60% of diabetic patients, while the prevalence of chronic diarrhea ranges from 4% to 22%. These variations in prevalence are attributed to differences in study populations and diagnostic criteria [3].
- **Nonalcoholic Fatty Liver Disease (NAFLD):** NAFLD is considered the hepatic manifestation of metabolic syndrome and is highly prevalent in individuals with type 2 diabetes.

Studies suggest that up to 70% of patients with type 2 diabetes may have NAFLD. A meta-analysis by Younossi et al. reported a pooled prevalence of NAFLD in diabetic individuals to be around 55.5% [6].

- Fecal Incontinence: Fecal incontinence, although less frequently studied, affects approximately 20% of patients with diabetes, significantly impacting their quality of life [2].



Figure 1: Gastro-intestinal manifestations of Diabetes Mellitus

Factors Influencing Prevalence

Several factors contribute to the variability in the reported prevalence of GI manifestations among diabetic patients, including

- **Type of Diabetes:** Type 1 diabetes (T1DM) patients, especially those with poor glycemic control, tend to have a higher prevalence of gastroparesis compared to those with type 2 diabetes (T2DM).
- **Duration of Diabetes:** The prevalence of GI symptoms increases with the duration of diabetes, reflecting the cumulative impact of hyperglycemia and autonomic neuropathy over time.
- **Glycemic Control:** Poor glycemic control is associated with a higher prevalence of GI symptoms, including gastroparesis and constipation.
- **Study Design and Population:** Variations in study design, diagnostic criteria, and the populations studied contribute to the wide range of reported prevalence rates.

Pathophysiology

The pathophysiology of GI manifestations in diabetes is multifactorial, involving hyperglycemia-induced damage, autonomic neuropathy, and alterations in GI motility and function.

- **Hyperglycemia-Induced Damage:** Chronic exposure to high glucose levels leads to the formation of advanced glycation end-products (AGEs), which can damage various tissues, including the nerves and smooth muscle of the GI tract. This damage can impair GI motility and lead to various GI symptoms [7].
- **Autonomic Neuropathy:** Diabetes can cause autonomic neuropathy, affecting the autonomic nerves that regulate GI motility. This can result in gastroparesis, where the stomach fails to empty properly, causing nausea, vomiting, and bloating. Autonomic neuropathy can also affect the lower GI tract, leading to constipation, diarrhea, and fecal incontinence [8].
- **Alterations in GI Motility:** Disruption in the normal motility patterns of the GI tract is a hallmark of diabetic GI manifestations. In gastroparesis, for example, there is delayed gastric emptying due to impaired gastric motor activity. Similarly, alterations in small and large bowel motility can lead to constipation or diarrhea [9].
- **Glycogenic Hepatopathy:** This condition, characterized by excessive accumulation of glycogen in hepatocytes, occurs predominantly in individuals with poorly controlled type 1 diabetes. Unlike NAFLD, glycogenic hepatopathy is reversible with improved glycemic control [10].
- **Microvascular Complications:** Diabetes-related microvascular complications can contribute to GI manifestations by impairing blood flow to the GI tract, further exacerbating the effects of neuropathy and leading to GI symptoms [11].

In conclusion, the pathophysiology is complex, involving hyperglycemia-induced damage, autonomic neuropathy, and alterations in GI motility and function, highlighting the systemic nature of diabetes and its extensive impact on the GI tract. Understanding these mechanisms is crucial for developing targeted interventions to manage and alleviate GI symptoms in individuals with diabetes.

Oral Disorders

Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, which results from defects in insulin secretion, insulin action, or both. The systemic nature of DM and its impact on various body systems, including the oral cavity, have been well documented in the literature. The oral manifestations of DM are multifaceted, affecting the teeth, periodontium, salivary glands, and mucosal surfaces, and are influenced by the degree of glycemic control, duration of diabetes, and presence of other complications associated with the disease [12].

Periodontal disease is one of the most significant oral complications associated with DM, with a bidirectional relationship between diabetes and periodontitis being widely recognized [13]. Diabetic patients exhibit an increased prevalence and severity of periodontitis, which can lead to tooth loss and has been associated with poor glycemic control [14]. The underlying mechanisms involve alterations in the host immune response, changes in the periodontal microflora, and impaired wound healing, all of which contribute to the progression of periodontal destruction [15]. Xerostomia, or dry mouth, is another common complaint and lead to an increased risk of dental caries, mucosal infections, and discomfort, significantly impacting the quality of life [16].

Oral candidiasis is more prevalent in diabetic patients, attributed to the elevated glucose levels in saliva that favor fungal growth and a compromised immune response that reduces the ability to combat infections[17]. It presents clinically as erythematous or pseudomembranous lesions, often accompanied by burning sensations and taste alterations. Delayed wound healing in the oral cavity attributed to microvascular changes, impaired immune response, and reduced collagen synthesis, poses a significant risk for post-surgical complications and persistent mucosal lesions [18].

Burning Mouth Syndrome (BMS) and taste alterations are other conditions reported in the diabetic population. BMS is characterized by a chronic burning sensation in the absence of visible mucosal changes, potentially linked to diabetic neuropathy [13].

Diabetic Gastroparesis

Diabetic Gastroparesis (DGP) is a significant complication of

diabetes mellitus, characterized by delayed gastric emptying in the absence of mechanical obstruction. This condition affects both type 1 and type 2 diabetes patients, with varying prevalence rates reported in the literature [19]. The pathophysiology of DGP involves a complex interplay of factors including hyperglycemia, autonomic neuropathy, alterations in the interstitial cells of Cajal, reduced expression of neural nitric oxide synthase, and increased oxidative stress. The clinical presentation of DGP can range from mild to severe symptoms, significantly impairing the quality of life and complicating glycemic control. Diagnosis is primarily based on symptoms and confirmed through gastric emptying studies such as scintigraphy, 13C breath tests, or wireless motility capsules [20]. Management strategies include dietary modifications, glycemic control, pharmacological interventions, and in severe cases, surgical options. Emerging therapies such as ghrelin receptor agonists and selective 5-hydroxytryptamine receptor agonists show promise [21].

- **Epidemiology:** The prevalence of DGP varies, with estimates suggesting that up to 50% of patients with long-standing type 1 and type 2 diabetes may experience delayed gastric emptying. The 10-year cumulative incidence of DGP has been estimated at 5.2% for type 1 diabetes patients and 1% for those with type 2 diabetes [22]. A study conducted in Olmsted County, MN, reported a prevalence of about 5% in type 1 diabetes and 1% in type 2 diabetes patients [19].
- **Pathophysiology:** DGP involves multiple pathophysiological mechanisms. Hyperglycemia and autonomic neuropathy play central roles, affecting gastric motility and leading to delayed gastric emptying. Alterations in the interstitial cells of Cajal, which are crucial for coordinating gastric contractions, and reduced expression of neural nitric oxide synthase further contribute to the condition. Oxidative stress and inflammation are also implicated in the pathogenesis of DGP [23].
- **Clinical Features:** Symptoms of DGP include nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. These symptoms can significantly impact patients' quality of life and complicate the management of diabetes by making glycemic control more challenging [24].
- **Diagnosis:** Diagnosis of DGP is based on clinical presentation and confirmed through gastric emptying studies. Gastric scintigraphy is considered the gold standard, but 13C breath tests and wireless motility capsules are also used. These diagnostic tools help differentiate DGP from other conditions with similar symptoms [22].
- **Management:** Management strategies for DGP focus on dietary modifications, glycemic control, and pharmacological interventions. Prokinetic agents such as metoclopramide and erythromycin are commonly used,however, ghrelin receptor agonists like relamorelin, show promise in alleviating symptoms and improving gastric emptying [20]. Surgical options, such as gastric electrical stimulation and pyloroplasty, are considered for severe cases refractory to medical treatment. These interventions aim to improve symptoms and gastric emptying, although their effectiveness varies among individuals.
- **Dietary Modifications:** Dietary adjustments are foundational in managing DGP. Patients are advised to consume small, frequent meals to avoid overwhelming the stomach. A low-fat and low-fiber diet is recommended since fats slow gastric emptying and fibers can form bezoars. Liquid meals or pureed foods may be better tolerated and can help ensure adequate nutrition. Patients should also be advised to chew food thoroughly and avoid lying down immediately after eating to facilitate gastric emptying [25].
- **Glycemic Control:** Optimizing blood glucose levels is crucial in managing DGP, as hyperglycemia can exacerbate gastric motility issues. Patients should work closely with their healthcare providers to adjust their diabetes management plan, which may include insulin therapy adjustments, oral hypoglycemic agents, and continuous glucose monitoring to prevent fluctuations in blood glucose levels that can affect gastric emptying [23,26].
-

Pharmacological Interventions

Several medications are used to manage DGP symptoms and improve gastric emptying

- **Prokinetic Agents:** Medications like metoclopramide and domperidone enhance gastric motility. Metoclopramide also has antiemetic properties but is associated with extrapyramidal side effects. Domperidone has fewer central nervous system side effects but may increase the risk of cardiac arrhythmias (Li, Unknown year).
- **Antiemetics:** Drugs such as ondansetron can help manage nausea and vomiting, although they do not affect gastric emptying.
- **Ghrelin Receptor Agonists:** Emerging treatments like relamorelin show promise in improving gastric emptying and alleviating symptoms of DGP (Li, Unknown year).
- **Antidepressants:** Tricyclic antidepressants may be used for their analgesic properties in managing abdominal pain associated with DGP, although their impact on gastric motility should be considered.

Endoscopic Management

It has emerged as a valuable approach in the treatment of Diabetic Gastroparesis (DGP), offering less invasive alternatives to traditional surgical interventions. This approach primarily focuses on techniques aimed at improving gastric emptying and alleviating the symptoms associated with DGP. The most notable endoscopic treatments include botulinum toxin injections, Gastric Peroral Endoscopic Myotomy (G-POEM), and the placement of venting or feeding tubes. These methods provide symptomatic relief and, in some cases, can improve gastric motility. Here, we delve into the specifics of these endoscopic management strategies, their mechanisms, efficacy, and potential limitations.

Botulinum Toxin Injections

Botulinum Toxin (Botox) injections into the pyloric sphincter have been explored as a treatment option for DGP. The rationale behind this approach is that botulinum toxin can inhibit acetylcholine release at the neuromuscular junction, leading to temporary relaxation of the pyloric sphincter, which could potentially improve gastric emptying. However, clinical trials have yielded mixed results. Some studies reported short-term improvement in gastric emptying and symptoms, while others, including randomized controlled trials, have not demonstrated significant benefits over placebo. The transient nature of botulinum toxin's effects, typically lasting a few months, and the variability in patient response limit its utility as a long-term solution for DGP [21,27].

Gastric Peroral Endoscopic Myotomy (G-POEM)

G-POEM is a novel endoscopic procedure adapted from the principles of peroral endoscopic myotomy (POEM) used for achalasia treatment. This technique involves creating a submucosal tunnel to access and perform a myotomy of the pyloric sphincter, thereby reducing pyloric resistance and improving gastric emptying. Early studies and case series have shown promising

results, with significant improvements in gastric emptying rates and symptom relief in patients with refractory gastroparesis. G-POEM appears to be particularly beneficial for patients with pylorospasm and refractory symptoms not responsive to medical therapy. Despite its potential, further research and long-term follow-up studies are needed to fully establish the efficacy, safety, and patient selection criteria for G-POEM in the management of DGP [19,20].

Venting and Feeding Tubes

In severe cases of DGP where oral intake is insufficient to meet nutritional needs or when refractory nausea and vomiting necessitate gastric decompression, endoscopic placement of venting or feeding tubes may be considered. A venting gastrostomy tube allows for the release of gastric gases and fluids, providing symptomatic relief from bloating and nausea. For nutritional support, a jejunostomy feeding tube can be placed endoscopically, enabling direct delivery of nutrients into the small intestine, bypassing the stomach. These interventions can be particularly useful in managing severe gastroparesis symptoms and preventing malnutrition. However, they are generally reserved for patients with severe, refractory DGP who have not responded to other treatments [22].

Surgical Options

Surgical options such as Pyloroplasty, gastrostomy or jejunostomy are usually reserved for severe DGP refractory to medical treatment.

Pancreatic Manifestations of Diabetes

The pancreas plays a central role in the pathophysiology of diabetes, not only as the organ responsible for insulin production but also as a target for diabetic complications. Chronic hyperglycemia and dyslipidemia associated with diabetes can lead to structural and functional changes in the pancreas, including pancreatic steatosis (fatty infiltration of the pancreas), fibrosis, and altered pancreatic exocrine function. These changes can contribute to the development of chronic pancreatitis, pancreatic cancer, and Exocrine Pancreatic Insufficiency (EPI) in individuals with diabetes

- **Pancreatic Steatosis:** Pancreatic steatosis, also known as nonalcoholic fatty pancreas disease (NAFPD), is characterized by the accumulation of fat deposits within the pancreas. This condition is increasingly recognized in individuals with Type 2 Diabetes Mellitus (T2DM) and obesity. Wagner discussed the association between pancreatic steatosis and insulin resistance, noting that pancreatic fat accumulation is linked to beta-cell dysfunction and impaired insulin secretion [28,29]. A study by van der Zijl et al. reported that individuals with T2DM had a significantly higher pancreatic fat content compared to healthy controls, suggesting a correlation between pancreatic steatosis and glycemic control. The presence of pancreatic fat has been implicated in the worsening of glucose homeostasis, emphasizing the need for strategies to reduce pancreatic fat as a means to improve insulin sensitivity and beta-cell function [30].
- **Chronic Pancreatitis:** Chronic pancreatitis in the context of diabetes is a condition marked by persistent inflammation leading to irreversible damage to the pancreatic tissue. Ewald et al, highlighted that diabetes increases the risk of developing chronic pancreatitis, and conversely, chronic pancreatitis can lead to a specific form of diabetes known as pancreatogenic diabetes or type 3c diabetes mellitus. The prevalence of chronic pancreatitis among individuals with diabetes is significant, with studies indicating that up to 80% of cases of type 3c diabetes mellitus are due to chronic pancreatitis. Management involves controlling hyperglycemia, dietary modifications, and pancreatic enzyme replacement therapy to address exocrine insufficiency [31].
- **Pancreatic Cancer:** The relationship between diabetes and pancreatic cancer is complex and bidirectional. Long-standing diabetes, is a significant risk factor for pancreatic cancer, with new-onset diabetes potentially serving as an early indicator of the disease. The prevalence of pancreatic cancer among diabetic individuals is notably higher, with a meta-analysis reporting a 1.5- to 2-fold increased risk of pancreatic cancer in patients with diabetes compared to those without. The pathophysiological mechanisms underlying this association may involve chronic inflammation, hyperinsulinemia, and insulin resistance, which promote pancreatic carcinogenesis. Early detection and management strategies are crucial for improving outcomes in this high-risk population [32]
- **Exocrine Pancreatic Insufficiency (EPI):** EPI is a condition characterized by inadequate production of pancreatic digestive enzymes, leading to malabsorption and nutritional deficiencies. Diabetes can cause EPI through mechanisms such as chronic pancreatitis or direct pancreatic damage. Patients with diabetes and EPI may experience symptoms such as steatorrhea, weight loss, and vitamin deficiencies. The management of EPI in diabetic patients includes pancreatic enzyme replacement therapy and dietary adjustments to improve nutritional status and quality of life [31].

Small Intestinal Manifestations

- **Small Intestinal Bacterial Overgrowth (SIBO):** SIBO is more prevalent in individuals with diabetes due to factors like autonomic neuropathy. Studies suggest that up to 50% of patients with diabetes may experience SIBO, compared to a lower prevalence in the general population. It generally manifests as bloating, diarrhea, and nutrient malabsorption. Breath tests are usually used for diagnosis, however, gold standard is culture of jejunal aspirate. The mainstay of treatment is rotating antibiotics.
- **Diabetic Diarrhea:** Diarrhea is a common GI symptom in diabetes, affecting approximately 20% of patients. This rate is significantly higher than in individuals without diabetes. The condition is often chronic and can be associated with nocturnal symptoms, contributing to discomfort and disrupted sleep. The underlying pathophysiological mechanism is diabetic autonomic neuropathy and SIBO. However, the medications such as metformin can also cause diarrhea.

Large Intestinal Manifestations

- **Constipation and Fecal Incontinence:** Constipation is reported in about 60% of diabetic patients, a rate nearly twice that observed in the general population. Fecal incontinence, although less frequently studied, also shows a higher prevalence in the diabetic population, influencing patients' social and psychological well-being.
- **Colorectal Cancer:** Individuals with diabetes have a 1.3 to 1.5 times higher risk of developing colorectal cancer compared to those without diabetes. This increased risk underscores the importance of regular screening and monitoring in the diabetic population. However, the guidelines regarding the regular surveillance colonoscopy in diabetic is still not recommended.

Conclusion

In conclusion, this review has elucidated the diverse gastrointestinal manifestations of diabetes, underscoring the significant burden of these complications on patient health and disease management. The intricate link between glycemic control and gastrointestinal symptoms necessitates a holistic, multidisciplinary management approach. Current literature points towards the gut microbiota's pivotal role, suggesting novel therapeutic avenues, yet highlighting the need for deeper mechanistic insights and tailored treatment strategies. Future research should focus on elucidating these mechanisms and evaluating new therapeutic interventions in rigorous clinical trials. Advancing our understanding in these areas is crucial for improving screening, early intervention, and ultimately, the quality of life for patients with diabetes.

References

1. Home, Resources, diabetes L with, Acknowledgement, FAQs, Contact, et al. Citation usage | IDF Diabetes Atlas https://diabetesatlas.org/citation-usage/.
2. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, et al. (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161: 1989-1996.
3. Krishnan B (2013) Gastrointestinal complications of diabetes mellitus. World J Diabetes 4: 51.
4. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, et al. (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97: 258-266.
5. Miftahussurur M, Nusi IA, Akil F, Syam AF, Wibawa IDN, et al. (2017) Gastric mucosal status in populations with a low prevalence of Helicobacter pylori in Indonesia. PLOS ONE 12: e0176203.
6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md 64: 73-84.
7. Ramzan Z, Duffy F, Gomez J, Fisher RS, Parkman HP (2011) Continuous glucose monitoring in gastroparesis. Dig Dis Sci 56: 2646-2655.
8. Phillips LK, Rayner CK, Jones KL, Horowitz M (2006) An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep 6: 417-423.
9. Ohlsson B, Melander O, Thorsson O, Olsson R, Ekberg O, et al. (2006) Oesophageal dysmotility, delayed gastric emptying and autonomic neuropathy correlate to disturbed glucose homeostasis. Diabetologia 49: 2010-2014.
10. Torbenson M, Chen YY, Brunt E, Cummings OW, Gottfried M, et al. (2006) Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Patho 30: 508-513.
11. Rayner CK, Samsom M, Jones KL, Horowitz M (2001) Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24: 371-381.
12. Lamster IB, Lalla E, Borgnakke WS, Taylor GW (2008) The relationship between oral health and diabetes mellitus. J Am Dent Assoc 139: 19-24.
13. Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, et al. (2012) Periodontitis and diabetes: a two-way relationship. Diabetologia 55: 21-31.
14. Löe H (1993) Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 16: 329-334.
15. Mealey BL, Ocampo GL (2007) Diabetes mellitus and periodontal disease. Periodontol 44: 127-153.
16. Navazesh M, Kumar SKS (2008) University of Southern California School of Dentistry. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 139: 35-40.
17. Darwazeh AM, MacFarlane TW, McCuish A, Lamey PJ (1991) Mixed salivary glucose levels and candidal carriage in patients with diabetes mellitus. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 20: 280-283.
18. Lalla E, Papapanou PN (2011) Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 7: 738-748.
19. Caturano A, Cavallo M, Nilo D, Vaudo G, Russo V, et al. (2024) Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions. Gastrointest Disord 6: 214-229.
20. Li L, Wang L, Long R, Song L, Yue R (2023) Prevalence of gastroparesis in diabetic patients: a systematic review and meta-analysis. Sci Rep 13: 14015.
21. Patel A, Arora GS, Roknsharifi M, Javed H, Kaur P (2023) Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety. Cureus 15: e48303.
22. Bharucha AE, Kudva YC, Prichard DO (2019) Diabetic Gastroparesis. Endocr Rev 40: 1318-1352.
23. Young CF, Moussa M, Shubrook JH (2020) Diabetic Gastroparesis: A Review. Diabetes Spectr Publ Am Diabetes Assoc 33: 290-297.
24. Goyal MK, Vuthaluru AR, Lal M (2022) Is there a Role of Anti-platelet Aggregation Agents in the Management of Primary Hypertension: An In-Vivo Study. FASEB J 36: e22386.
25. Shin AS, Camilleri M (2013) Diagnostic Assessment of Diabetic Gastroparesis. Diabetes 62: 2667-2673.
26. Goyal MK, Mehta V, Prakash S, Grover K, Gupta Y, et al. (2023) Liver stiffness measurement as a surrogate marker of clinically significant portal hypertension. J Clin Exp Hepatol 13: 36-37.
27. Goyal MK, Mehta V, Ahuja A, Sood N, Gupta Y, et al. (2023) To Assess the Efficacy of Bariatric Surgery as a Treatment Modality of NAFLD. J Clin Exp Hepatol 13: 139.
28. Wagner R, Jaghutriz BA, Gerst F, Barroso Oquendo M, Machann J, et al. (2020) Pancreatic Steatosis Associates With Impaired Insulin Secretion in Genetically Predisposed Individuals. J Clin Endocrinol Metab 105: 3518-3525.
29. Luthra M, Mehta V, Bedi G, Gupta Y, Goyal M (2023) Study of Risk Factors in Patient with Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease with Mild Elevation of Transaminases. J Clin Exp Hepatol 13: 123-124.
30. Pezzilli R, Calculli L (2014) Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? World J Diabetes 5: 415-419.
31. Ewald N, Hardt PD (2013) Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol WJG 19: 7276-7281.
32. Amri F, Belkhayat C, yeznasni A, Koulali H, Jabi R, et al. (2023) Association between pancreatic cancer and diabetes: insights from a retrospective cohort study. BMC Cancer 23: 856.